Our CEO and founder Ali Salanti will be delivering an invited talk alongside other European and global leaders innovating in the antibody drug conjugate (ADC) space at the 15th World ADC London conference, scheduled to take place in London between March 3rd and 6th . Ali will share with the audience our recent progress in […]
GRONINGEN, NETHERLANDS (21 January 2025) – TRACER and VAR2 Pharma announce the first patient enrolled in the VARTUTRACE study, a Phase 0 first-in-human imaging trial (NCT06645808). The patient, suffering from lung carcinoma received the Investigational Medicinal Product (IMP), a zirconium-89-labeled single-chain variable fragment (scFv), Vartumab, on Dec 17, 2024. The patient successfully completed all study […]
Our team is attending the World ADC Event Series taking place in San Diego between Nov 4-7. Our CEO Ali Salanti will be accompanied by Tobias Gustavsson, Swati Choudhary, Robert Dagil and Thomas Clausen. We are looking forward to meeting old and new partners to discuss synergies around our lead ADC based on first-in-class antibodies […]
GRONINGEN, NETHERLANDS (30 September 2024) – VAR2 Pharmaceuticals ApS (‘VAR2 Pharma’) has received regulatory approval for their first-in-human Phase 0 clinical trial. In this study, the safety, tolerability, and biodistribution of two zirconium-89 labeled single-chain variable Fragments (scFvs) will be evaluated using PET/CT molecular imaging. The Danish company VAR2 Pharma is collaborating with TRACER, a […]
Our team is attending ESMO 2024 in Barcelona! VARCT Dx’s CSO, Mette Ørskov Agerbæk and VAR2 Pharma’s COO Frederico Pimenta will be there and are looking forward to catching up on the most recent developments in oncology. Come meet us at our poster #218P on Sunday to hear more about our latest work on using […]
The development of cancer is accompanied by a change in the composition of a sugar molecule called chondroitin sulfate. This sugar molecule becomes unusually long and heavily sulfated. For years, VAR2 has pursued the development of cancer therapeutics targeting this secondary modification called oncofetal chondroitin sulfate. But until recently, the known difficulties in generating antibodies […]
The development of CTC-derived models specific to PDAC has remained challenging due to the limited number of CTCs retrieved from patients’ samples. In work led by our collaborators, we demonstrated that our proprietary recombinant VAR2CSA, which specifically binds oncofetal chondroitin sulfate, retrieved more live CTCs than single antibodies for traditional CTC biomarkers (EpCAM, CD7, […]
After years of R&D efforts VAR2 Pharma is finally ready to present our novel proprietary cancer targeting antibodies. The antibodies targeting oncofetal chondroitin sulfate have demonstrated very high broad solid tumor specificity and preclinical PoC for antibody-drug conjugate (ADC) applications in different cancer disease models. We are now looking for partners in the pharmaceutical industry […]
This publication out today in ACS Nano, VAR2 Pharma co-authors report proof-of concept for how oncofetal chondroitin sulfate on cancer cells can be targeted by nanoparticle-formulations of red blood cells. This system builds on a natural binding-module mediating attachment of malaria-infected red blood cells to oncofetal chondroitin sulfate presented in the placental and malignant tissue […]
VAR2 Pharma’s co-authors have published new work on how the VAR2 Pharma rVAR2 proteins are internalized into tumor cells after binding to cell surface proteoglycans. The cell fate of rVAR2 proteins is important in the context of chondroitin sulfate targeting strategies, in particular our drug-delivery technology, currently in pre-clinical development phase. Read more: https://www.nature.com/articles/s41598-022-07025-6
Our website only uses strictly necessary cookies. Please consult our Privacy Policy for additional information on how we process your data.
